R. Bouamar

发表

The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation

D. Hesselink, L. Elens, T. Gelder, 2014, Clinical Pharmacokinetics.

Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial

J. Burger, R. Mathijssen, I. de Hingh, 2019, BMJ Open.

Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial.

W. Weimar, D. Hesselink, T. van Gelder, 2018, The Netherlands journal of medicine.

A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype‐Based With Body‐Weight‐Based Tacrolimus Dosing After Living Donor Kidney Transplantation

W. Weimar, D. Hesselink, M. C. Clahsen‐van Groningen, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.

V. Haufroid, D. Hesselink, R. V. van Schaik, 2011, Clinical chemistry.

Genetic Polymorphisms in ABCB1 Influence the Pharmacodynamics of Tacrolimus

W. Weimar, D. Hesselink, R. V. van Schaik, 2013, Therapeutic drug monitoring.

The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity

D. Hesselink, T. van Gelder, R. Bouamar, 2010, Therapeutic drug monitoring.

Follicular T helper cells and humoral reactivity in kidney transplant patients

D. Roelen, F. Claas, W. Weimar, 2015, Clinical and experimental immunology.

Polymorphisms of the glucocorticoid receptor and avascular necrosis of the femoral heads after treatment with corticosteroids

W. Weimar, T. van Gelder, E. V. van Rossum, 2009, NDT plus.

Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant.

D. Hesselink, K. Caliskan, A. Balk, 2017, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients

V. Haufroid, D. Hesselink, R. V. van Schaik, 2012, Pharmacogenetics and genomics.

Mycophenolic acid-related anemia and leucopenia in renal transplant recipients are related to genetic polymorphisms in CYP2C8.

W. Weimar, D. Hesselink, R. V. van Schaik, 2012, Transplantation.

Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

D. Hesselink, R. V. van Schaik, T. van Gelder, 2014, British journal of clinical pharmacology.

Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are Not Associated With Cyclosporine Pharmacokinetics Nor With Cyclosporine Clinical End Points After Renal Transplantation

J. D. de Fijter, W. Weimar, D. Hesselink, 2011, Therapeutic drug monitoring.

Individualization of Immunosuppressive Therapy after Solid Organ Transplantation

R. Bouamar, 2014 .

Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients

J. D. de Fijter, W. Weimar, D. Hesselink, 2012, Pharmacogenetics and genomics.

Genetic polymorphisms in IL‐2, IL‐10, TGF‐β1, and IL‐2RB and acute rejection in renal transplant patients

J. D. de Fijter, W. Weimar, A. Hartmann, 2014, Clinical transplantation.

ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation.

W. Weimar, D. Hesselink, R. V. van Schaik, 2012, Clinica chimica acta; international journal of clinical chemistry.

Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized‐Controlled Clinical Trials †

W. Weimar, D. Hesselink, B. Kaplan, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus Clearance

W. Weimar, D. Hesselink, R. V. van Schaik, 2011, Therapeutic drug monitoring.

Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose

Rachida Bouamar, Teun van Gelder, D. Hesselink, 2017, Transplantation direct.

The Optimal MMF Dose in Tacrolimus Treated Patients

W. Weimar, D. Hesselink, B. Kaplan, 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients

V. Haufroid, J. D. de Fijter, K. Budde, 2013, Therapeutic drug monitoring.

Functionality test for drug safety alerting in computerized physician order entry systems

Jos Aarts, Heleen van der Sijs, Teun van Gelder, 2010, Int. J. Medical Informatics.

The Pharmacogenetics of Calcineurin Inhibitor–Related Nephrotoxicity

D. Hesselink, T. van Gelder, R. Bouamar, 2010, Therapeutic drug monitoring.

The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients

V. Haufroid, D. Hesselink, R. V. van Schaik, 2012, Pharmacogenetics and genomics.